Back to first-pass browser

First-pass extracted concept

adeno-associated viruses

Candidate: toolkit itemType: delivery harness2 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

AAV, AAVs

Extracted Explainers

What the tool is doing

AAVs are described as delivery vectors for optogenetic approaches in retinal disease models.

Source 1DOIPubMed

AAVs are described as the delivery vectors used in retinal disease models for optogenetic therapy. They carry the optogenetic payload into retinal tissue.

Source 1DOIPubMed

AAVs are used here as the in vivo delivery vehicle for the FUS-CRISPR system.

Source 2DOIPubMed

Resources required

Their use requires retinal administration by intravitreal or subretinal injection.

Source 1DOIPubMed

Their use requires vector production and ocular administration, specifically intravitreal or subretinal injection according to the abstract.

Source 1DOIPubMed

This requires packaged viral vectors carrying the relevant CRISPR components, although the abstract does not specify vector details.

Source 2DOIPubMed

What problem it solves

They solve the need to deliver optogenetic genetic material to retinal target cells.

Source 1DOIPubMed

They solve the delivery problem for getting optogenetic constructs into retinal cells.

Source 1DOIPubMed

It provides a way to deploy the ultrasound-inducible CRISPR system in vivo.

Source 2DOIPubMed

What it does not solve

The abstract does not show that AAV delivery fully resolves targeting, efficacy, or translational safety challenges.

Source 1DOIPubMed

The abstract does not indicate that AAV delivery alone provides inducible control; the control layer comes from focused ultrasound-triggered activation.

Source 2DOIPubMed

Alternatives

No alternative delivery vector is explicitly named in the abstract.

Source 1DOIPubMed

No alternative delivery vector class is named in the abstract.

Source 1DOIPubMed

Evidence Snippets

In retinal disease models, adeno-associated viruses (AAVs) serve as delivery vectors via intravitreal or subretinal injections.
Evidence 1Source 1DOIPubMedprovenance
We further deliver FUS-CRISPR in vivo using adeno-associated viruses (AAVs)...
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1challenge statementsupports2025Source 1DOIPubMed

Clinical translation of optogenetic therapy for AMD faces challenges and requires further development.

Claim 2delivery rolesupports2025Source 1DOIPubMed

AAVs serve as delivery vectors in retinal disease models via intravitreal or subretinal injections.

Quoted textsource-backed
In retinal disease models, adeno-associated viruses (AAVs) serve as delivery vectors via intravitreal or subretinal injections.
Claim 3delivery usagesupports2025Source 1DOIPubMed

In retinal disease models, AAVs serve as delivery vectors for optogenetic approaches via intravitreal or subretinal injection.

Claim 4review scopesupports2025Source 1DOIPubMed

The paper discusses optogenetic tools, delivery methods, challenges, future directions, preclinical AMD models, and clinical translation potential for AMD-related vision loss.

Quoted textsource-backed
This review explores the principles of optogenetics, its application in preclinical AMD models, and the potential for clinical translation of this approach. We discuss the various optogenetic tools, delivery methods, and the challenges and future directions in harnessing this technology to combat AMD-related vision loss.
Claim 5delivery applicationsupports2024Source 2DOIPubMed

FUS-CRISPR was delivered in vivo using AAVs.

Quoted textsource-backed
We further deliver FUS-CRISPR in vivo using adeno-associated viruses (AAVs)...